» Authors » Stephane Leonce

Stephane Leonce

Explore the profile of Stephane Leonce including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 293
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian W, Yougnia R, Depauw S, Lansiaux A, David-Cordonnier M, Pfeiffer B, et al.
J Med Chem . 2014 Nov; 57(24):10329-42. PMID: 25360689
A series of 6-methoxy-3,3,14-trimethyl-3,14-dihydro-7H-benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one (4), 13-aza derivatives of benzo[b]acronycine, the isomeric 5-methoxy-2,2,13-trimethyl-2,13-dihydro-6H-benzo[b]chromeno[7,6-g][1,8]naphthyridin-6-one (5), and related cis-diols mono- and diesters were designed and synthesized. Their in vitro and in vivo biological...
2.
Burbridge M, Bossard C, Saunier C, Fejes I, Bruno A, Leonce S, et al.
Mol Cancer Ther . 2013 Jun; 12(9):1749-62. PMID: 23804704
Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been associated with tumor progression in a wide variety of human malignancies, notably in instances of primary or...
3.
Lescoat G, Leonce S, Pierre A, Gouffier L, Gaboriau F
Chem Biol Interact . 2011 Dec; 195(2):165-72. PMID: 22197641
If a new generation of iron chelators specifically devoted for cancer chemotherapy emerged these last years, any of them has not yet been approved at this time. Accordingly, there is...
4.
Ferry G, Studeny A, Bossard C, Kubara P, Zeyer D, Renaud J, et al.
Life Sci . 2011 Jul; 89(7-8):259-68. PMID: 21736880
Aims: We have developed biochemical and cell based assays to characterize small therapeutic molecules that inhibit the DNA damage checkpoint enzyme, Chk1 (Checkpoint kinase 1). Main Methods: To prepare a...
5.
Gaslonde T, Covello F, Velazquez-Alonso L, Leonce S, Pierre A, Pfeiffer B, et al.
Eur J Med Chem . 2011 Mar; 46(5):1861-73. PMID: 21411193
The impact of substitutions at position 10 in the A ring of the cytotoxic benzo[a]acronycine and benzo[b]acronycine series has been explored. 10-Bromobenzo[a] and 10-bromobenzo[b]acronycine were prepared in 12% and 15%...
6.
Sancier F, Dumont A, Sirvent A, Paquay de Plater L, Edmonds T, David G, et al.
PLoS One . 2011 Mar; 6(2):e17237. PMID: 21390316
c-Yes, a member of the Src tyrosine kinase family, is found highly activated in colon carcinoma but its importance relative to c-Src has remained unclear. Here we show that, in...
7.
Verones V, Flouquet N, Farce A, Carato P, Leonce S, Pfeiffer B, et al.
Eur J Med Chem . 2010 Oct; 45(12):5678-84. PMID: 20884092
The synthesis of new 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives along with their activity in cell-free enzymatic assays on Src is reported. Some compounds emerged as moderately active inhibitors of the enzyme and showed...
8.
Ayerbe N, Routier S, Gillaizeau I, Maiereanu C, Caignard D, Pierre A, et al.
Bioorg Med Chem Lett . 2010 Jun; 20(15):4670-4. PMID: 20566289
We report the efficient synthesis and biological evaluation of new benzodioxinoindolocarbazoles heterocycles (BDCZs) designed as potential anticancer agents. Indolic substitution and maleimide variations were performed to design a new library...
9.
Boutefnouchet S, Minh N, Putrus R, Pfeiffer B, Leonce S, Pierre A, et al.
Eur J Med Chem . 2009 Nov; 45(2):581-7. PMID: 19926174
In order to explore the structure-activity relationships in the acronycine and psorospermin series, simplified analogues of the highly cytotoxic (+/-)-(2R*,1'R*)-5-methoxy-11-methyl-2-(2-methyloxiran-2-yl)-1,2-dihydro-11H-furo[2,3-c]acridin-6-one and (+/-)-(2R*,1'R*)-5-methoxy-13-methyl-2-(2-methyloxiran-2-yl)-1,2-dihydro-13H-benzo[b]furo[3,2-h]-acridin-6-one lacking the fused furan ring, including 3-allyloxy-1-methoxy-10-methyl-acridin-9(10H)-one, 3-allyloxy-1-methoxy-5-methyl-benzo[b]acridin-12(5H)-one,...
10.
Cahuzac N, Studeny A, Marshall K, Versteege I, Wetenhall K, Pfeiffer B, et al.
Cancer Lett . 2009 Sep; 289(2):178-87. PMID: 19758748
The biochemical pathways that lead cells to mitotic catastrophe are not well understood. To identify these pathways, we have taken an approach of treating cells with a novel genotoxic compound...